What is the dosage of Kesimpta?

Kesimpta is available in 1 dosages, including 50 mg/ml Pen Injector 0.4 ml

What does Kesimpta treat?

Kesimpta treats Lymphoid Leukemia

What is Kesimpta made of?

Kesimpta contains ofatumumab which is a CD20-directed Cytolytic Antibody

How is Kesimpta administered?

Kesimpta is administered as a Injectable

What is Kesimpta mechanism of action?

Kesimpta mechanism of action is CD20-directed Antibody Interactions

Kesimpta

(ofatumumab)

0.4 ML ofatumumab 50 MG/ML Pen Injector [Kesimpta]

NO BLACK BOX WARNING

Dosage & administration

* Hepatitis B virus (HBV) and quantitative serum immunoglobulins screening are required before the first dose.
* Administer KESIMPTA by subcutaneous injection only.
* Initial Dosing: 20 mg administered at Weeks 0, 1, and 2.
* Subsequent Dosing: 20 mg administered monthly starting at Week 4.

Most viewed Kesimpta resources

Letter of Medical Necessity - New Treatment

Letter of Medical Necessity - Change of Treatment

Coverage Authorization Appeal - New Treatment

Coverage Authorization Appeals - Change of Treatment

drug label

Kesimpta prescribing information

Have more Kesimpta questions?

Submit MSL Request

Learn More

Need to report a Kesimpta issue?

ONLINE FORMReport adverse event

Learn More

samples

Request Kesimpta samples

Complete Online sample form

Learn More

prior authorization

Kesimpta Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Letter of Medical Necessity - New Treatment

Letter of Medical Necessity - Change of Treatment

Coverage Authorization Appeal - New Treatment

Coverage Authorization Appeals - Change of Treatment

Learn More

Benefits investigation

Kesimpta Start Form

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Kesimpta Financial assistance options

Co-pay savings program

commercial only

Enroll in patient savings program - English ( Physician Initiated)

Enroll in Patient Savings Program - Spanish ( Physician Initiated)

Enroll in patient savings program ( Patient Initiated)

Kesimpta Start Form

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Enroll in Bridge Program

Kesimpta Start Form

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Novartis Patient Assistance Foundation Application - English

Novartis Patient Assistance Foundation Application - Spanish

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement